Join us Tuesday, June 27, 2017 at 1:00 pm EDT, 10:00 am PDT, 12:00 pm CDT for a Genomeweb Webinar.
HTG and GenomeWeb host a Webinar with guest speaker, Dr. Kenneth Huffman, Senior Research Scientist, Hamon Center for Therapeutic Oncology Research University of Texas Southwestern Medical Center at Dallas
A QIAGEN interview with John Lubniewski at the 2017 ASCO Conference on the importance of Immuno-Oncology
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has amended and restated its IVD Test Development and Component Supply Agreement with Illumina to, among other things, extend the agreement term and increase the number of in-vitro diagnostic (IVD) test kits that may be developed for use with Illumina sequencing technology.
Join us Saturday, May 27 through Tuesday, May 30, 2017 at ESHG 2017 in Copenhagen, Denmark.
HTG will be in Copenhagen at the 2017 ESHG Conference. Stop by to learn more about our NGS-based sequencing assays that are automated on the HTG EdgeSeq system.
HTG is proud to support Red Nose Day and we’re doing our part to end child hunger.
TUCSON, Ariz., May 15, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the three months ended March 31, 2017.
Join us Friday, June 02, 2017 through Tuesday, June 06, 2017 at McCormick Place in Chicago, IL.
HTG will be at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Stop by and learn how our NGS-based HTG EdgeSeq chemistry and automation can help shape the future of oncology.
TUCSON, Ariz., May 01, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 first quarter results after market close on Monday, May 15, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, May 15 to discuss these results and answer questions.
TUCSON, Ariz., April 24, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a research collaboration agreement with Instituto Valenciano de Oncología (IVO). The initial project, utilizing the HTG EdgeSeq Oncology Biomarker Panel, will focus on the development and validation of a breast cancer recurrence risk score, based on genes that are differentially expressed between patients with low and high risk of recurrence.
TUCSON, Ariz., April 17, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, announced that it has entered into a research agreement with Centre Léon Bérard, which provides the framework for molecular profiling studies aimed to advance precision medicine. The initial project utilizes the HTG EdgeSeq Oncology Biomarker Panel to retrospectively characterize immunologic profiles from advanced malignant tumor samples collected in the ProfiLER study (ClinicalTrials.gov identifier NCT01774409).
TUCSON, Ariz., April 17, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that, on April 12, 2017, the company received formal notice from The NASDAQ Stock Market LLC indicating that the Nasdaq Hearings Panel had granted the Company’s request to transfer the listing of HTG’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market based upon HTG’s compliance with all requirements for continued listing on the latter market. The intra-market transfer took effect upon the open of trading this morning, Monday, April 17, 2017.
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a master services agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for work to be performed in HTG’s VERI/O laboratory.
Page last updated March 20, 2023